Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Granisetron versus sufentanil for prevention of etomidate-induced myoclonus
IRCT20210221050436N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- May 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of granisetron, sufentanil and etomidate in myoclonus (3 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Intensity of myoclonus movements after intravenous etomidate injection. Started May 2021; status: completed.
02
Drugs
granisetronsufentaniletomidate
03
Conditions
myoclonus
Beyond the preview
Go deeper on IRCT20210221050436N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210221050436N1.